The QLattice finds the best siRNA activity model by searching the space of feaures and combinations.
Background and key takeaways.
Here we use the QLattice to generate siRNA activity models from publicly available data to create insights that can be used to design active siRNAs.
With explainable AI in the form of symbolic regression, we can get an improved understanding of what drives drug properties in conjunction with accurate drug property predictions.
Importantly, the workflow presented here can also be used to predict any desired outcome such as toxicity, duration or even be used for disease understanding and target identification.
- We generate Model A: a highly accurate activity model for unmodified siRNAs.
- The model reveals that there are specific dimers at the first and last positions of the duplex that are more or less beneficial.
- However, an siRNA with unfavourable dimers at named positions can still be active with the right target binding energy (whole ΔG).
- Nevertheless, an siRNA with the worst possible first and last dimers cannot be saved by an optimal binding energy.
- Interestingly, fully chemically modified siRNAs do not fit model A indicating that other features drive the activity for these.
- Model B is therefore generated using the same input features as used for Model A but trained on data from chemically modified siRNAs. It is showing improved predictability for modified siRNAs.
- In general Model A has a poor performance on modified siRNAs and Model B has a poor performance on unmodified siRNAs suggesting different main drivers of activity for these two classes of siRNAs.
Abzu's poster of our siRNA activity models:
Explainable AI: Designing better molecules to become drugs.
Understanding what drives drug properties — in conjunction with accurate drug activity predictions — is a clear advantage to improving drug candidate hit rates.
Here we use the QLattice to generate siRNA activity models from publicly available data to create insights that can be used to design active siRNAs.
Download our poster from the 19th Annual Meeting of the Oligonucleotide Therapeutics Society 2023.
Download our poster:
Explainable AI: Designing better molecules to become drugs.
Entering your information does not subscribe you to marketing emails from Abzu. We just worked really hard on this research, and we want to know more about you.
Entering your information above does not subscribe you to marketing emails from Abzu. It just makes it easier for us to get in touch with you.
Leading in short oligonucleotide innovation and design.
Precision RNA therapeutics with ASOs, siRNAs, and antimiRs.
We’re redefining the potential of RNA therapeutics through our specialized workflow with ASOs, siRNAs, and antimiRs.
This focus ensures our therapeutics have high activity and exhibit minimal off-target effects, heralding a new era of precision medicine.